Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP

Pharmacists step into cardiovascular prevention with patient education, statin protocols, and new prescribing training—if clinical work gets paid.

Pharmacists unpack easier access to PCSK9 inhibitors and inclisiran—smart prior auth, Medicare Part B nuances, and foundation help that cuts costs.

Paste the article text (or an excerpt), and I’ll generate a 150-character, 24-word max SEO meta description in present tense.

Pharmacists drive new cholesterol care: educate patients, tackle prior auth and cost barriers, and improve adherence to statins and

Pharmacists speed cholesterol guideline adoption through patient education, prior auth support, and adherence fixes for

Learn how clinicians tailor add-on lipid therapies—PCSK9s, ezetimibe, bempedoic acid—using shared decisions, follow-up, and statin myths.

Please paste the article text (or a link/excerpt). I’ll generate an SEO-friendly meta description (≤24 words, ≤150 characters) in present tense.

Learn how CAC scores, PREVENT ASCVD, and Lp(a) reshape risk talks—help pharmacists personalize statins, targets, and follow‑up.

Learn how CAC scans, PREVENT ASCVD scoring, and Lp(a) testing sharpen risk talks and guide statin choices in pharmacy practice.

Panelists examine how LDL-C targets vary by cardiovascular risk level and highlights the role of pharmacists and multidisciplinary teams in delivering effective patient education to improve adherence and long-term outcomes.

Panelists explore how treatment goals differ between primary and secondary cardiovascular prevention, emphasizing risk stratification, guideline application, and strategies to optimize long-term outcomes through individualized, multidisciplinary care.

Craig Beavers and Kyle Fischer debrief on key late-breaking cardiovascular trials from the 2026 American College of Cardiology Scientific Sessions.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Host Craig Beavers reviews key studies and insights from the upcoming ESC Congress 2025, focusing on groundbreaking research in cardiology and treatment advancements.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions.

Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota

The panel concludes its discussion with insights on successful strategies that can inform optimal collaborative care practices for cardiovascular risk reduction in patients with ASCVD.

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.